Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001998851 | SCV002276330 | likely pathogenic | Glycogen storage disease, type II | 2023-01-13 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 1483591). This variant has not been reported in the literature in individuals affected with GAA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 928 of the GAA protein (p.Tyr928His). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GAA protein function. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Tyr928 amino acid residue in GAA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 29122469, 33741225). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. |